Car T-Cell Therapy

Jakub Svoboda, MD, of Penn Medicine, discussed data from the ZUMA-12 study presented at the ASH Annual Meeting and Exposition.

The FDA cleared an investigational new drug application for PBCAR19B, a chimeric antigen receptor T-cell therapy for patients with relapsed or refractory non-Hodgkin lymphoma, according to the agent’s manufacturer.

CAR T-cell therapy can serve as a frontline treatment option for patients with high risk B-cell lymphomas with CD-19 CAR T-cells, according to a presentation from ASH Annual Meeting and Exposition.

Neetu Gupta, PhD, associate professor at Cleveland Clinic Foundation, discussed her thoughts on influential topics to appear at the next the ASH Annual Meeting and Exposition.

Neetu Gupta, PhD, associate professor at Cleveland Clinic Foundation, discussed data comparing cytokine release syndrome in CAR T-therapy to COVID-19 at the ASH Annual Meeting and Exposition.

Neetu Gupta, PhD, associate professor at Cleveland Clinic Foundation, discussed exciting CAR-T presentations featured at the ASH Annual Meeting and Exposition, including new targets for lymphoid malignancies and CAR modifications to improve safety.

Adoptive cell therapies have proved highly effective for patients with certain advanced cancers, particularly melanoma and hematologic malignancies.

The value of chimeric antigen receptor T-cell therapy for patients with heavily pretreated multiple myeloma can be significant, regardless of whether it leads to a complete and lasting remission.

Ninety percent of patients with relapsed B-cell acute lymphoblastic leukemia after allogeneic stem cell transplantation had complete response to an investigational chimeric antigen receptor T-cell therapy, according to preliminary data.

John P. Chute, MD, has been appointed director of the division of hematology and cellular therapy in the department of medicine at Cedars-Sinai Cancer.